Stocktoria
Kiniksa Pharmaceuticals International, plc KNSA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-05-24
Kiniksa Pharmaceuticals International, plc financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $677.6M | $423.2M | $270.3M | $220.2M | $38.5M |
| R&D expense | $96.9M | $111.6M | $76.1M | $65.5M | $99.3M |
| SG&A expense | $196.3M | $168.0M | $129.4M | $98.0M | $85.9M |
| Operating income | $77.2M | -$45.6M | -$25.2M | $9.8M | -$156.6M |
| Income tax | $29.9M | $7.0M | -$30.7M | -$172.3M | $1.4M |
| Net income | $59.0M | -$43.2M | $14.1M | $183.4M | -$157.9M |
| EPS (diluted) | $0.75 | $-0.60 | $0.20 | $2.60 | $-2.30 |
| Operating cash flow | $138.0M | $25.7M | $13.3M | $5.8M | -$126.3M |
| Free cash flow | $136.4M | $25.4M | $13.2M | $5.7M | -$126.7M |
| Cash & equivalents | $165.6M | $183.6M | $108.0M | $122.7M | $122.5M |
| Inventory | $54.9M | $26.4M | $31.1M | $21.6M | $3.7M |
| Total assets | $763.6M | $580.6M | $526.3M | $459.7M | $232.8M |
| Total liabilities | $196.0M | $142.1M | $87.5M | $63.5M | $47.8M |
| Shareholders' equity | $567.6M | $438.4M | $438.8M | $396.1M | $185.0M |
Source: SEC EDGAR filings · CIK 0001730430 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.